Skip to main content

Novel anti-angiogenic treatment for cancer, arthritis and ocular neo-vascularization based on inhibition of Placental Growth Factor (PlGF)

Objective

The widening gap between Pharmaceutical R&D spending and the approval of innovative medicines is a matter of concern both in the US, and in the EU and forms the basis for FP6 topic LSH-2005-1.2.1-3. This project proposes a comprehensive approach to develop a new, safe and more effective medicine that reduces (anti-angiogenic) pathological blood vessel formation. Overgrowth of blood vessels causes a.o. solid tumour growth, ocular neovascularization (diabetic retinopathy and macular degeneration) and rheumatoid arthritis. The proposed drug target is Placental Growth Factor (PlGF) and the candidate drug is a humanized neutralizing monoclonal antibody. This drug target selection is based on: 1) recent basic research at the Flanders Interuniv. Inst. for Biotechn. (VIB-3, Belgium) on the role of PlGF in pathological angiogenesis; 2) intellectual property owned by or licensed to ThromboGenics (TX/TG, Ireland); 3) relevant 'translational research' by most of the partners (BioInvent, BI, Sweden; TX/TG; VIB-3; Cardiff University, CU, UKi) that established proof of concept in experimental animal models that inhibition of PlGF reduced solid tumour growth and improved ocular neovascularization and arthritis; 4) initial 'critical path research' experience at the preclinical level (BI, TX/TG, VIB-3, Charité Berlin, Germany; University Hospital Leuven, Belgium; and CU); and 5) GMP manufacturing capabilities (BI). Although the development of anti-angiogenic compounds has thus far been dominated by US-based biopharmaceutical research, the proposed European Consortium possesses unique assets (both know-how and intellectual property) to play a dominant role in the development of new, safer and more effective anti-angiogenic medicines. This SME driven STREP could lead to significant advancement of the drug candidate program and will form the basis for a long-term industrial and commercial collaboration among the SMEs and their academic collaborators.

Call for proposal

FP6-2005-LIFESCIHEALTH-7
See other projects for this call

Funding Scheme

STREP - Specific Targeted Research Project

Coordinator

BIOINVENT INTERNATIONAL AB (PLC)
Address
Sölvegatan 41
Lund
Sweden

Participants (5)

THROMBOGENICS LIMITED
Ireland
Address
14 Bridgecourt Office Park, Walkinston Avenue
Dublin
FLANDERS INTERUNIVERSITY INSTITUTE FOR BIOTECHNOLOGY VZW
Belgium
Address
Rijvisschestraat 120
Zwijnaarde
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
Address
Oude Markt 13
Leuven
CARDIFF UNIVERSITY
United Kingdom
Address
30-36 Newport Road
Cardiff
CHARITÉ, UNIVERSITAETSMEDIZIN BERLIN, CAMPUS VIRCHOW-KLINIKUM, MEDIZINISCHE KLINIK MIT SCHWERPUNKT HEPATOLOGIE UND GASTROENTEROLOGIE
Germany
Address
Augustenburger Platz 1
Berlin